Mallinckrodt™ Pharmaceuticals

Technical Bulletin

Ref: **TB-17002-ENG**

Issue date: February 2022

Product: INOmax DS$_{IR}$®, INOmax DS$_{IR}$® Plus, INOmax DS$_{IR}$® Plus MRI and INOflo DS®

Priority: Low

Affected parts: INOmax DS$_{IR}$, INOmax DS$_{IR}$ Plus, INOmax DS$_{IR}$ Plus MRI and INOflo DS

Classification: Information for Distribution

Subject: **Purging the Regulator Supply Line and/or the Delivery System**

This technical bulletin is written to advise clinicians that testing has been completed which demonstrates that the INOmax DS$_{IR}$, INOmax DS$_{IR}$ Plus, INOmax DS$_{IR}$ Plus MRI and INOflo DS may stand idle for 24 hours after a successful Pre-Use procedure and depressurization of the regulator(s) has been completed.
If the device is not placed into use within these 24 hours repeat the Pre-Use procedure.

⚠ **WARNING: If the INOmax DS$_{IR}$, INOmax DS$_{IR}$ Plus, INOmax DS$_{IR}$ Plus MRI or INOflo DS is depressurized and is not used on a patient within 24 hours, repeat the pre-use procedure.**

For technical assistance regarding any of the above devices, please contact Technical Support at 1-877-566-9466 (North America) or your specific country manager.

Mallinckrodt Manufacturing LLC
6603 Femrite Drive,
Madison, WI 53718-6801 USA

Ref: TB-17002-ENG Created 02-2022
PN 21465, rev. 02

EC REP

Europe
European Authorized Representative
MDSS GmbH
Schiffgraben 41
30175 Hannover, Germany

CE
2797

Ref: TB-17002-ENG Created 02-2022
PN 21465, rev. 02